The University of Chicago Header Logo

Connection

James Dignam to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications James Dignam has written about Prostatic Neoplasms.
James Dignam
Connection Strength
2.671
Prostatic Neoplasms
  1. Detecting a Survival Benefit to Dose Escalation-Reply. JAMA Oncol. 2019 01 01; 5(1):110.
    View in: PubMed
    Score: 0.269
  2. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 01 20; 37(3):213-221.
    View in: PubMed
    Score: 0.268
  3. Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer. Stat Med. 2016 09 30; 35(22):3933-48.
    View in: PubMed
    Score: 0.223
  4. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012 Apr 15; 18(8):2301-8.
    View in: PubMed
    Score: 0.166
  5. Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115). Int J Radiat Oncol Biol Phys. 2025 Dec 01; 123(5):1247-1258.
    View in: PubMed
    Score: 0.106
  6. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol. 2025 Sep; 88(3):277-290.
    View in: PubMed
    Score: 0.105
  7. Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 Dec; 201:110532.
    View in: PubMed
    Score: 0.100
  8. Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 Feb; 22(1):3-10.
    View in: PubMed
    Score: 0.098
  9. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. Eur Urol. 2025 Feb; 87(2):217-224.
    View in: PubMed
    Score: 0.098
  10. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2024 Jul 10; 42(20):2377-2381.
    View in: PubMed
    Score: 0.098
  11. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278.
    View in: PubMed
    Score: 0.096
  12. Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies. Eur Urol. 2023 09; 84(3):331-340.
    View in: PubMed
    Score: 0.092
  13. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
    View in: PubMed
    Score: 0.083
  14. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.
    View in: PubMed
    Score: 0.079
  15. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
    View in: PubMed
    Score: 0.074
  16. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743.
    View in: PubMed
    Score: 0.074
  17. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983.
    View in: PubMed
    Score: 0.070
  18. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 01; 5(5):664-670.
    View in: PubMed
    Score: 0.069
  19. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 09 20; 35(27):3097-3104.
    View in: PubMed
    Score: 0.061
  20. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):296-303.
    View in: PubMed
    Score: 0.059
  21. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428.
    View in: PubMed
    Score: 0.059
  22. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 07 10; 34(20):2325-32.
    View in: PubMed
    Score: 0.056
  23. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 01; 33(4):332-9.
    View in: PubMed
    Score: 0.051
  24. Assessing treatment benefit with competing risks not affected by the randomized treatment. Stat Med. 2015 Jan 30; 34(2):265-80.
    View in: PubMed
    Score: 0.050
  25. A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. Clin Cancer Res. 2014 Dec 15; 20(24):6379-88.
    View in: PubMed
    Score: 0.050
  26. Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation. Stat Methods Med Res. 2016 12; 25(6):2972-2991.
    View in: PubMed
    Score: 0.049
  27. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007 Feb 15; 109(4):802-10.
    View in: PubMed
    Score: 0.030
  28. Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease-Free Survival. Biom J. 2025 Aug; 67(4):e70064.
    View in: PubMed
    Score: 0.027
  29. Flexible modeling of the hazard rate and treatment effects in long-term survival studies. Stat Methods Med Res. 2017 Oct; 26(5):2455-2480.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.